



NEUESTE FORSCHUNGSERKENNTNISSE ZU HEPATITIS C

Claude Scheidegger, Basel

Bienna/Biel, 29. September 2016




Neue Therapien: Heilungsraten

Varia (zu aktuellen Forschungsgebieten)

- Hepatitis C Kaskade
- Extrahepatische Manifestationen
- Risikoverlauf nach Heilung
- Reinfektionsrisiko
- Hepatitis C Elimination




Recombinant type I IFN-based therapy in chronic hepatitis C



2013
Heim M. Nature Reviews | Immunology



Recombinant type I IFN-based therapy in chronic hepatitis C



Heim M. Nature Reviews | Immunology

2013



Recombinant type I IFN-based therapy in chronic hepatitis C

Treated patients who showed an SVR (%)



2013
Heim M. Nature Reviews | Immunology

HCV-TARGET Real-World Cohort
SVR12 Results with LDV/SOF±RBV for 8, 12, and 24 Weeks (Per Protocol Analysis)





Figure 1. SVR12 by baseline factor

Pooled ASTRAL Studies (ASTRAL-1, ASTRAL-2, ASTRAL-3)


SOF/VEL STR for 12 Weeks



‡



Terault, AASLD, 2015; 94




AVIATOR Study: paritaprevir/ritonavir + ombitasvir + dasabuvir + ribavirin in genotype 1a

SVR₂₄ (HCV RNA < 25 IU/ml)

PTV/r + OBV + DSV + RBV 8W PTV/r + OBV + RBV 12W PTV/r + OBV + DSV + RBV 12W PTV/r + OBV + DSV + RBV 24W

PTV/r + OBV + DSV 12W PTV/r + OBV + DSV + RBV 12W PTV/r + OBV + DSV + RBV 24W




SVR₂₄ in naïve cohort genotype 1a (76-94%) vs 1b (96-100%); odds ratio : 0.087 [p = 0.0008]

AVIATOR

Kowdley KV. NEJM 2013; 370:222-32

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opioid replacement therapy

SVR₁₂ (HCV RNA < 15 IU/ml) in the immediate treatment group, by subgroup, % (95% CI), ITT, Full analysis set *



* Reinfection = failure

Dore GJ. Ann Intern Med 2016; Aug 9 (Epub ahead of print)





Figure 1. SVR12 by baseline factor




HCV = hepatitis C virus; RNA = ribonucleic acid; SVR12 = sustained virologic response 12 weeks post-treatment.

AVIATOR Study: paritaprevir/ritonavir + ombitasvir + dasabuvir + ribavirin in genotype 1a

SVR₂₄ (HCV RNA < 25 IU/ml)

Legend:

- PTV/r + OBV + DSV + RBV 8W
- PTV/r + OBV + RBV 12W
- PTV/r + OBV + DSV + RBV 12W
- PTV/r + OBV + DSV 12W
- PTV/r + OBV + DSV + RBV 24W




SVR₂₄ in naïve cohort genotype 1a (76-94%) vs 1b (96-100%); odds ratio : 0.087 [p = 0.0008]

AVIATOR

Kowdley KV. NEJM 2013; 370:222-32

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opioid replacement therapy

SVR₁₂ (HCV RNA < 15 IU/ml) in the immediate treatment group, by subgroup, % (95% CI), ITT, Full analysis set *



* Reinfection = failure

Dore GJ. Ann Intern Med 2016; Aug 9 (Epub ahead of print)






Figure 1. SVR12 by baseline factor

Turville, AASLD, 2015; 94



HCV = hepatitis C virus; RNA = ribonucleic acid; SVR12 = sustained virologic response 12 weeks post-treatment




Pooled ASTRAL Studies (ASTRAL-1, ASTRAL-2, ASTRAL-3)

SOF/VEL STR for 12 Weeks



D JJ, et al. N Engl J Med. 2015. DOI: 10.1056/NEJMoa1512610. Sulkowski, AASLD, 2015; 205. Foster GR, et al. New Engl J Med. 2015. DOI: 10.1056/NEJMoa1512612.

C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opioid replacement therapy



AVIATOR

Kowdley KV. NEJM 2013; 370:222-32



‡ Augustus C


95-100% Heilung bei allen Patienten



C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opioid replacement therapy

HCV-trials.com

SVR₁₂ (HCV RNA < 15 IU/ml) in the immediate treatment group,
by subgroup, % (95% CI), ITT, Full analysis set *




* Reinfection = failure



C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opioid replacement therapy

HCV-trials.com

SVR₁₂ (HCV RNA < 15 IU/ml) in the immediate treatment group,
by subgroup, % (95% CI), ITT, Full analysis set *



* Reinfection = failure


Alter median 48 Jahre, F4 20%, pos. UP 62%



C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opioid replacement therapy

HCV-trials.com

SVR₁₂ (HCV RNA < 15 IU/ml) in the immediate treatment group,
by subgroup, % (95% CI), ITT, Full analysis set *



* Reinfection = failure






C-EDGE CO-STAR: grazoprevir/elbasvir for HCV infected drug users on opioid replacement therapy

HCV-trials.com

SVR₁₂ (HCV RNA < 15 IU/ml) in the immediate treatment group,
by subgroup, % (95% CI), ITT, Full analysis set *




* Reinfection = failure

Pooled ASTRAL Studies (ASTRAL-1, ASTRAL-2, ASTRAL-3)

‡

SOF/VEL STR for 12 Weeks




Feld, AASLD, 2015, LB-2. Feld JJ, et al. *N Engl J Med.* 2015. DOI: 10.1056/NEJMoa1512610. Sulkowski, AASLD, 2015, 205. Foster GR, et al. *New Engl J Med.* 2015. DOI: 10.1056/NEJMoa1512612. Mangia, AASLD, 2015, 249. Foster GR, et al. *New Engl J Med.* 2015. DOI: 10.1056/NEJMoa1512612.



Pooled ASTRAL Studies (ASTRAL-1, ASTRAL-2, ASTRAL-3)

‡

SOF/VEL STR for 12 Weeks



Feld, AASLD, 2015, LB-2. Feld JJ, et al. *N Engl J Med.* 2015. DOI: 10.1056/NEJMoa1512610. Sulkowski, AASLD, 2015, 205. Foster GR, et al. *New Engl J Med.* 2015. DOI: 10.1056/NEJMoa1512612. Mangia, AASLD, 2015, 249. Foster GR, et al. *New Engl J Med.* 2015. DOI: 10.1056/NEJMoa1512612.





PERFECTOVIR

- > 90% Heilungsraten
- minimale Nebenwirkungen
- wirksam gegen alle Genotypen
- Dosierung 1x pro Tag
- kurze Therapien
- tiefer Preis



PERFECTOVIR

- > 90% Heilungsraten ✓
- minimale Nebenwirkungen ✓
- wirksam gegen alle Genotypen (✓)
- Dosierung 1x pro Tag ✓
- kurze Therapien 8-12 Wochen ✓
- tiefer Preis



PERFECTOVIR

- > 90% Heilungsraten ✓
- minimale Nebenwirkungen ✓
- wirksam gegen alle Genotypen (✓)
- Dosierung 1x pro Tag ✓
- kurze Therapien 8-12 Wochen ✓
- tiefer Preis ☹



5g of diamonds

25 1-carat (\$1900 each)

Cost = \$48,000



5g of xxxxxvir

12 weeks of treatment, 60mg/day

Cost = \$63,000 (US price)






Neue Therapien: Heilungsraten


Varia (zu aktuellem Forschungsgebieten)

- Hepatitis C Kaskade
- Extrahepatische Manifestationen
- Risikoverlauf nach Heilung
- Reinfektionsrisiko
- Hepatitis C Elimination

Hepatitis C Kaskade





HCV Test, Care, and Cure Continuum



SAM M S U

Swiss Association for the Medical Management in Substance Users



Metavir F	n	%
1	74	50%
2	17	12%
3	22	15%
4	34	23%
Total chronic HCV with fibrosis info	147	100%

Outcome	n	%
SVR	62	62%
Response	66	66%
Failure not defined	1	1%
Nonresponse	1	1%
Poor response	1	1%
Total patients with fibrosis, completed and outcome determined	76	100%

Extrahepatische Manifestationen



- Kryoglobulinämie
- Unterschiedliche Hauterkrankungen
- Glomerulonephritis
- Lymphom
- Diabetes mellitus
- Schilddrüsenerkrankungen
- Kognitive Veränderungen, Fatigue
- ...

Extrahepatische Manifestationen



INHSU September 07 2016:

Effective Antiviral Treatment Reduces Fatigue in People with Hepatitis C


“The researchers concluded that fatigue in people living with chronic hepatitis C cannot be solely explained by substance use or opioid substitution therapy, but it could be linked to HCV-related measures including liver inflammation, fibrosis, and sustained treatment response.”



Prurigo nodularis


Risikoverlauf nach Heilung

Figure 1. Clinical outcomes according to virologic response status




Risikoverlauf nach Heilung

Figure 1. Clinical outcomes according to virologic response status




Reinfektionsrate erhöht bei jüngeren Drogenkonsumierenden?



Verschiedene Studien, Übersicht Grady B et al CID 2013

HCV treatment as prevention: Edinburgh



Martin N et al Hepatology 2013





Unterstützungen

- *Honorare für Beratungen/Vorträge*

AbbVie, BMS, Gilead, MSD

- *Reise- und Tagungsspesen*

AbbVie, BMS, Gilead, MSD, Roche, ViiV

- *Projekte*

AbbVie, MSD, Roche, ViiV

Verbindungen, Mandate und Kontakte

EKSG, SSI, nationale Hepatitis Strategie, Infodrog, BAG